PURPOSE The PRIMA study (ClinicalTrials. gov identifier: NCT00140582) established that 2
years of rituximab maintenance after first-line immunochemotherapy significantly improved …

Abstract The intergroup PRIMA Phase III study was designed to investigate the potential
benefit of 2-years of rituximab maintenance in patients with follicular lymphoma (FL) …

Background Patients with follicular lymphoma can have long survival times, but disease
progression typically occurs 3–5 years after initial treatment. We assessed the potential …

In a previous systematic review and meta-analysis of five randomized controlled trials
comparing rituximab maintenance with no maintenance (observation or rituximab at …

Background Follicular lymphoma is characterized by slow growth and an initially high rate of
response to treatment, but patients typically relapse and experience progressive disease …

Purpose In 2006, we published the results of the European Organisation for Research and
Treatment of Cancer phase III trial EORTC 20981 on the role of rituximab in remission …

E1496 is a phase III trial designed to evaluate the ability of 2 years (yr) of maintenance
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …

We evaluated the role of rituximab (R) both in remission induction and maintenance
treatment of relapsed/resistant follicular lymphoma (FL). A total of 465 patients were …

Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …

Phase 2 studies suggest that the monoclonal antibody rituximab may improve the prognosis
of patients with follicular lymphoma (FL) when it is added to chemotherapy. In the current …